Clopidogrel
NDC 31722-902
Product Information
Clopidogrel is a ANDA-approved product labeled by Camber Pharmaceuticals, Inc.. Clopidogrel is used to prevent heart attacks and strokes in persons with heart disease (recent heart attack), recent stroke, or blood circulation disease (peripheral vascular disease). It is supplied as a pink product. This product entry covers the primary NDC 31722-902 and 4 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
OVAL (C48345)
19 MM
SG;124
SG;121
Code Structure Chart
Product Details
What is NDC 31722-902?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CLOPIDOGREL BISULFATE (UNII: 08I79HTP27)
- CLOPIDOGREL (UNII: A74586SNO7) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- MANNITOL (UNII: 3OWL53L36A)
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- HYDROXYPROPYL CELLULOSE (TYPE H) (UNII: RFW2ET671P)
- HYPROMELLOSES (UNII: 3NXW29V3WO)
- CASTOR OIL (UNII: D5340Y2I9G)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- POLYETHYLENE GLYCOLS (UNII: 3WJQ0SDW1A)
- FERRIC OXIDE RED (UNII: 1K09F3G675)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 309362 - clopidogrel 75 MG Oral Tablet
- RxCUI: 309362 - clopidogrel 75 MG (as clopidogrel bisulfate 97.875 MG) Oral Tablet
- RxCUI: 749196 - clopidogrel 300 MG Oral Tablet
- RxCUI: 749196 - clopidogrel 300 MG (as clopidogrel bisulfate 391.5 MG) Oral Tablet
* Please review the full disclaimer at the bottom of this page.